📖IMSPARK: Pacific Research Must Be Relational, Not Extractive📖

📖Imagine… Research Guided by Pacific Culture and Ethics📖

💡 Imagined Endstate:

Imagine a research culture where Pacific peoples, knowledge systems, languages, and lived experiences are not treated as data sources, but as partners in knowledge creation. Research would begin with respect, move through relationship, and return value to the communities that made the work possible.

📚 Source:

Pacific Research & Policy Centre and Pasifika@Massey Directorate. Pacific Research Guidelines and Protocols. Massey University. link.

💥 What’s the Big Deal: 

Imagine a future where every research project involving Pacific peoples begins with relationship and ends with return🌱. Ethical research is about avoiding harm and about creating knowledge in a way that strengthens dignity, agency, and community benefit. Pacific research should not simply study the Pacific. It should serve the Pacific.

The Pacific Research Guidelines and Protocols make clear that research involving Pacific peoples cannot be treated as a purely technical process🪴. It is not just about designing a study, collecting data, coding responses, and publishing results. In Pacific contexts, research is relational. It involves families, communities, and accountability.

The big deal is that Pacific research must move away from extractive habits. Too often, communities are studied, quoted, categorized, and interpreted without receiving meaningful benefit, control, or voice in how their knowledge is represented⛲️. A Pacific-centered approach asks stronger questions: Who benefits from this research? Who defines the problem? Who interprets the findings? Who owns the knowledge? Who is responsible when the research is done?

This matters because knowledge is never neutral when power is uneven🧭. Researchers often bring institutional authority, funding access, academic language, and publication power. Ethical research requires humility so academic systems do not overpower the people whose realities they are trying to understand.

Pacific research protocols remind us that method is more than technique🪢. Interviews, observations, and analysis must be grounded in values such as respect, reciprocity, service, consent, care, and relationship. In this sense, the “how” matters as much as the “what.” A study can have a strong design and still cause harm if it treats people as subjects instead of partners.

For Pacific scholars and practitioners, this is also a self-efficacy issue🛶. Pacific communities should not have to wait for outside institutions to define their challenges, measure their strengths, or explain their futures. Pacific-led research supports communities in producing knowledge that reflects their own priorities, not just external agendas.

This also connects to policy and funding🧱. If decision-makers rely on research that lacks Pacific grounding, they may design programs that miss local realities. Strong Pacific research guidelines help ensure that evidence is culturally meaningful, community-informed, and useful for action.

 

#PacificResearch, #ResearchEthics, #MasseyUniversity, #PacificKnowledge, #Reciprocity, #CommunityAccountability, #PacificLeadership, #IMSPARK, 

🧪IMSPARK: FDA Innovation Beyond Animal Testing🧪

🧪Imagine… Science Powered by Animal-Relevant Technology🧪

💡 Imagined Endstate:

Imagine a biomedical innovation system where drug and device development relies less on animal testing and more on validated, human-relevant tools such as organ-on-chip models, advanced computer simulations, artificial intelligence, digital twins, and ethical data-driven research methods.

📚 Source:

Berman, J. R., & Seeley, A. Z. (2026, March 24). Innovation at the FDA: Efforts to decrease animal testing and usher in new technologies. Morgan Lewis. link.

💥 What’s the Big Deal: 

Berman and Lewis (2026) explain that the FDA is signaling a major shift in how it may evaluate new medical products. On March 18, 2026, FDA released draft guidance on using New Approach Methodologies, or NAMs, in drug development, following a broader roadmap for phasing out animal testing. These methods include human-derived in-vitro systems such as organ-on-chip, computer modeling and simulation, and other innovative testing platforms designed to improve prediction of human toxicology while reducing reliance on animal studies🛡️.

The big deal is that this is not only an animal welfare issue. It is also a science, speed, cost, and public health issue🧬. Animal models do not always predict human outcomes well, and traditional development pathways can be slow and expensive. If new tools can better reflect human biology, they may help researchers identify safety risks earlier, design better trials, reduce unnecessary testing, and move promising therapies toward patients more efficiently.

But innovation still needs guardrails🧾. The FDA draft guidance focuses on whether a NAM is appropriate for its intended regulatory use, including context of use, human biological relevance, technical characterization, and whether the method is fit for purpose. Berman and Lewis note some uncertainty because the guidance suggests validation helps determine data quality, while also stating that a NAM may not always need to be fully validated to be considered in drug development. That flexibility creates opportunity, but it also requires careful judgment.

The challenge is even more complex for medical devices⚙️. They note that FDA has encouraged NAMs in areas such as biocompatibility studies, but regulatory science gaps remain, including a shortage of validated or qualified NAMs for certain device assessments. That means the move away from animal testing will not happen evenly across all product areas. Drugs, devices, biologics, software, and combination products may each need different evidence pathways.

This shift also opens the door for technology companies🤖. AI, machine learning, digital twins, 3D tissue models, decentralized trial tools, and simulation platforms may become increasingly important in product development and clinical trials. But companies entering this space must understand that health innovation is highly regulated. Privacy, research ethics, data integrity, good clinical practices, risk controls, and compliance are not optional extras; they are the foundation for trust.

Imagine a future where biomedical research is faster, more ethical, and more human-relevant without lowering safety standards🔬. The big deal is this: reducing animal testing should not mean reducing rigor. It should mean building better methods, stronger evidence, and smarter oversight so innovation serves patients, protects participants, and advances science responsibly.

#FDAInnovation, #AnimalTestingAlternatives, #NewApproachMethodologies, #OrganOnChip, #BiomedicalInnovation, #ResearchEthics, #RegulatoryScience, #IMSPARK